Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

7%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
11(73.3%)
Phase 2
3(20.0%)
Phase 3
1(6.7%)
15Total
Phase 1(11)
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT07174427Phase 3Recruiting

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Role: lead

NCT02869217Phase 1Active Not Recruiting

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Role: collaborator

NCT05963217Phase 1Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Role: collaborator

NCT03153085Phase 2Completed

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

Role: lead

NCT03252808Phase 1Active Not Recruiting

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Role: lead

NCT03250325Phase 1Completed

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Role: lead

NCT03155191Phase 1Active Not Recruiting

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Role: lead

NCT03259425Phase 2Terminated

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Role: collaborator

NCT02096614Phase 1Completed

Investigator Initiated Phase 1 Study of TBI-1201

Role: collaborator

NCT02418598Phase 1Terminated

AADC Gene Therapy for Parkinson's Disease

Role: collaborator

NCT01017185Phase 1Completed

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Role: lead

NCT02366546Phase 1Unknown

Investigator Initiated Phase 1 Study of TBI-1301

Role: collaborator

NCT02272855Phase 2Completed

A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Role: lead

NCT02428036Phase 1Completed

A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

Role: lead

NCT02134262Phase 1Unknown

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Role: collaborator

All 15 trials loaded